Usefulness of neuron-specific enolase as a serum marker of metastatic melanoma

Source: MDLinx, August 2020

Given that the likely usefulness of serum neuron-specific enolase (sNSE) as a marker for melanoma has been suggested in some previous reports, but there is controversy regrading its usefulness, so, researchers retrospectively assessed sNSE as well as serum lactate dehydrogenase (sLDH) concentrations at the initial diagnosis and during therapy in a total of 33 melanoma patients of various stages.

Using enzyme?linked immunosorbent assay, NSE levels were examined in cell lysates and supernatants from melanoma cell lines. In stage IV patients vs stages I/II and III, a significantly higher median sNSE was detected.

In stage IV, the coincidence rate of sNSE and sLDH was 11 of 18 (61.1%) at the initial diagnosis. Of all four melanoma cell lines, NSE was identified in both supernatant and cell lysate (0.30–237.32 ng/mL and 137–483.04 ng/mg, respectively).

READ THE ORIGINAL FULL ARTICLE